SGEN - Seattle Genetics Inc.

35.74 -0.01 (-0.03%)

Investor Rating: 0

Rate SGEN A Buy Rate SGEN A Sell

Be the first investor to rate this stock.

NasdaqGS: SGEN Stock Quote

Last Trade: 35.74   Day's Range: 35.50 - 36.20
Trade Time: 3:22pm   52wk Range: 17.09 - 39.00
Change: -0.01 (-0.03%)   Volume: 315,346
Prev Close: 35.75   Avg Vol (3m): 820,286
Open: 36.03   Market Cap: 4.334B
Bid: 35.72 x 100   P/E (ttm): N/A
Ask: 35.74 x 100   EPS (ttm): -0.486
1y Target Est: 32.42   Div & Yield: 0.00 (N/A)


NasdaqGS: SGEN Overview

Seattle Genetics, Inc. (Seattle Genetics) is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer and autoimmune diseases. Its product candidate, brentuximab vedotin (SGN-35), is being developed for the treatment of diseases, which express an antigen called CD30 present on multiple cancer types, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL). It also has collaborations for its antibody-drug conjugate (ADC) technology with a range of biotechnology and pharmaceutical companies. In addition, it has four other clinical-stage programs: SGN-75, ASG-5ME, dacetuzumab (SGN-40) and SGN-70. In September 2010, it discontinued its lintuzumab (SGN-33) development program.


Comments & Rumors On SGEN
Please sign-in to post a comment, or register for a free SmallCap Network account.
Have something to say about SGEN? Just type something in the box above.
Member Analysis Of SGEN
Analysis
SGEN Research Media
File

Member Blog Posts On SGEN
20
Mon
Sep 20, 2010 10:07 AM PDT
16
Mon
Aug 16, 2010 11:12 AM PDT
Blog
Members Picking SGEN
Pick
Other News and Information on SGEN

No Message Board Sources. Submit New Ones By Clicking Here.



Do you know of another great research resource for SGEN that belongs here? Please let us know and provide the URL.

Join the 200,000+ other Members who take full advantage of all the SmallCap Network has to offer: Sign In or Join